FDA fast-tracks Shire's Vyvanse for binge eating; Merck starts shipping Keytruda;

@FiercePharma: Tops in FP this weekend: Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets. Article | Follow @FiercePharma

@EricPFierce: Apotex, which has had plenty of cGMP issues of its own, is recalling generic Paxil made at GSK plant. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it every week, subscribe here. | Follow @CarlyHFierce

> Shire's ($SHPG) ADHD drug Vyvanse scored a priority review at the FDA for a potential new use to treat binge eating disorder. Report

> Merck ($MRK) has already started shipping its brand-new cancer immunotherapy Keytruda, approved last week to treat melanoma. Report

> Patient groups put Germany at the top of the list of countries with the best access to medicines, with the U.S. tied for 7th place. Report

> A potential antidote to quickly reverse the blood-thinning effects of Boehringer Ingelheim's Pradaxa is moving into a clinical trial, to be conducted in emergency rooms in 35 countries. Report

Medical Device News

@FierceMedDev: ICYMI: ReWalk squeaks by with $36M IPO as oncology device player Mevion files to raise up to $69M. Article | Follow @FierceMedDev

@MichaelGFierce: HIV-fighting intravaginal ring research nets $20M from NIH. FierceDrugDelivery story | Follow @MichaelGFierce

> Medtronic launches wearable cardiac monitor acquired from Corventis. Article

> iPod touch to be used for diabetes monitoring following launch of HealthKit. Story

> Medtronic unveils new study showing 2-year success of its TAVR device. More

Biotech News

@FierceBiotech: Arch, Polaris back a $20M round for Scholar Rock's immune system R&D platform. Article | Follow @FierceBiotech

@JohnCFierce: This $AVNR "drug" is what gives biotech a bad name--simply awful. | Follow @JohnCFierce

@DamianFierce: ICYMI: $BIIB and $ABBV plan to market the monthly MS shot daclizumab as Zinbryta, filing in 2015. Release | Follow @DamianFierce

@EmilyMFierce: Well, this is an interesting development. Nature reviewers not persuaded by initial STAP stem cell papers. More from Science | Follow @EmilyMFierce

> Avanir skyrockets as its controversial generic combo claims a hit in PhII Alzheimer's study. Report

> Cancer R&D stars pitch an $86M biotech IPO for Kolltan Pharma. Story

> Roche's Genentech triggers its PhIII program for blockbuster AMD contender. News

CRO News

> Evotec signs a Huntington's deal as diabetes project falls through. Report

> Quintiles homes in on small biotechs with new service offering. More

> Recruitment specialist Trialbee snags a deal with AstraZeneca. Item

> Icon and Medidata unite to give patients a louder voice in clinical trials. Article

> PRA swings for $375M in the next big CRO IPO. News

Biotech IT News

> Wearables project aims to provide new source of data for MS trials. Story

> Application of regulatory handbrake to 23andMe offers cautionary tale to Silicon Valley. Report

> NCI turns to Dell for pediatric cancer research project. More

> AstraZeneca taps Trialbee for online patient recruitment. Article

> Mayo Clinic to apply IBM's Watson to matching patients to trials. Story

Animal Health News

> FDA seeks input on conditional approvals for new animal health products. Report

> Merck launches new vaccine to fight PRRS in pig herds. More

> European Commission adds new proposals for use of veterinary meds and medicated feed. Story

> Alivira snaps up 60% stake in Turkey's Provet Veterinary Products. Article

> Dechra Pharmaceuticals reports gains in full-year profit. Report

And finally ... Indian officials plan to sit down with Big Pharma execs worried about the country's patent-fighting policies to hear their concerns. Report

Suggested Articles

Mylan recalls one lot of the injectable antibiotic daptomycin after discovering particles in a single-dose vial.

AbbVie's Allergan received a positive early ruling in its long-running trade secrets dispute with Evolus over a competitor to blockbuster Botox.

As Amgen ramps up clinical trials of its psoriasis drug Otezla in COVID-19, it might also be studying its blockbuster Enbrel in fighting the virus.